IMMUNE-MEDIATED ENDOCRINOPATHY

This adverse event was reported 150 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED ENDOCRINOPATHY:

# Drug Count
0 PEMBROLIZUMAB 77
1 NIVOLUMAB 66
2 IPILIMUMAB 51
3 PACLITAXEL 28
4 PACLITAXEL (AIBUMIN-BOUND) 28
5 BEVACIZUMAB 22
6 CARBOPLATIN 17
7 PEMETREXED DISODIUM 7
8 ATEZOLIZUMAB 5
9 CYCLOPHOSPHAMIDE 3
See all common drugs associated with IMMUNE-MEDIATED ENDOCRINOPATHY

IMMUNE-MEDIATED ENDOCRINOPATHY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 NIVOLUMAB AND RELATLIMAB-RMBW 1 0.0019
1 IPILIMUMAB 51 0.0012
2 PEMBROLIZUMAB 77 0.0007
3 NIVOLUMAB 66 0.0007
4 LEVOLEUCOVORIN INJECTION 2 0.0007
5 LEVOLEUCOVORIN 2 0.0005
6 CEMIPLIMAB-RWLC 1 0.0005
7 DOSTARLIMAB 1 0.0004
8 SITAGLIPTIN PHOSPHATE 1 0.0004
9 DANAZOL 1 0.0004
See all drugs enriched for association with IMMUNE-MEDIATED ENDOCRINOPATHY